Executive Team

Bobby V. Khan, MD, PhD, Executive Director

Dr. Bobby Khan is a cardiologist and clinical investigator. He serves as Professor of Medicine at the University of Central Florida School of Medicine. He has published nearly 90 peer-reviewed articles in the areas of cardiovascular and metabolic disorders in highly regarded scientific journals. In 2009, he was awarded a Fulbright Research Chair to work at the University of Prince Edward Island with Dr. Tarek Saleh, Chairman of Biomedical Sciences, and his research group. Dr. Khan’s Fulbright scholarship has allowed him to come to Canada on several occasions over the past five years. His work has been extremely productive and has resulted in the production of multiple research manuscripts and the submission of patents on developed intellectual property. He has served as the principal investigator for several clinical trials. He has obtained research support from the National Institutes of Health and private companies. He has served on several planning committees for the scientific sessions of the American College of Cardiology and the American Heart Association. He is the holder of several patents in the area of Treatment for Atherosclerosis and Other Cardiovascular and Inflammatory Diseases.

Frank Kelly, Director of Business and Marketing

Mr. Kelly worked twenty-four years with The Coca-Cola Company, holding various executive positions with both U.S. and global responsibilities including Japan. He most recently served as Vice-President of The Coca-Cola Company and President/CEO of Coca-Cola Nestle Refreshment Company. Mr. Kelly also previously worked with the Pepsi-Cola Bottling Company and later PepsiCo International, serving as President and Representative Director for Japan. He is an emeritus member of Board of Directors for the following companies: Hygea Health Holdings, InVasc Therapeutics, Entaire Global Companies and is Chairman of the Advisory Board of Rainmaker Financial Group Inc., Chicago, IL. Mr. Kelly also serves on the Board of Directors and Executive Committee for the National Arthritis Foundation and is Trustee Emeritus at Bentley University. He attended the Harvard University Business School MBA program and holds a B.S. in Accounting and Finance from Bentley University.

Nadya Merchant, PhD, MPH, Commercialization Management

Dr. Merchant has extensive experience with the design and implementation of clinical trials. She has been intrinsically involved in clinical trial regulatory affairs and takes a key role in formulating the preclinical drug development plan for Carmel Biosciencescompounds. As the Chief Commercialization Officer, Dr. Merchant is actively involved in developing the commercialization strategies for Carmel Biosciencescompounds through vital partnerships with larger pharmaceutical companies. Dr. Merchant received her doctorate in Nutrition from the Graduate School of Arts and Sciences at Emory University. She has a Masters degree in Public Health and International Nutrition from the Rollins School of Public Health. Her research focused on the effects of lipid-modifying and oxidative compounds on atherosclerosis development. Her background and expertise in human nutrition gives the company a valuable advantage in the nutraceutical arena. She has nearly ten years of experience in drug development. She has presented at various conferences including those of the American Heart Association, American College of Cardiology, The Southeast Lipid Research Conference and The Oxygen Society and has a number of publications.

Ray Carreon, Business Development Operations

Mr. Carreon was involved in the sales division for Zuellig Pharma, a leading pharmaceutical distribution in Southeast Asia, for several years.  He has 25 years combined experience in pharmaceutical sales, technology, data analysis and management, business analysis, project management and implementation, operations administration, consulting, and global business development with Zuellig Pharma, Alcon Laboratories, IBM, Aon-Hewitt Associates, and Molor Products. He has extensive international relationships and was instrumental with the global expansion of Molor new products, establishing rapid growth in new markets all across Asia, Europe, and the Middle East. Mr. Carreon holds advanced university degrees in Philosophy and Computer Information Systems  Currently, he serves as a Clinical Operations Director with Atlanta Clinical Research Center.

William Schaeffer, Operations Management

Mr. Schaeffer most recently was COO and on the Board of Directors for InVasc Therapeutics, Inc., a pharmaceutical development company.  From 2006 to 2009, he was V.P., Global Head of Quality for Ciba Vision Inc. (a Novartis company).  Prior to joining Ciba Vision, Mr. Schaeffer was President of the American Cardiovascular Research Institute, a translational medical research organization, which merged to establish the Saint Joseph’s Research Institute focused on accelerating development of cutting-edge therapies in cardiovascular medicine.  Experienced with start-ups and the FDA, as COO for Ortec International, Inc., he led them to two FDA product approvals and first stage commercialization.  Mr. Schaeffer began his career with Johnson & Johnson where he spent 28 years in a variety of senior management positions.  During his tenure, he was integral to the development of several products and five start-up companies.  Prior to leaving JNJ, he was Vice President, Quality Assurance Worldwide for Cordis, Inc. and on their Management Board. Mr. Schaeffer serves as an Elder in the Peachtree Presbyterian Church, is on the Board of the Iota Chapter of Kappa Delta Rho, and annually does international mission work. He holds a B.S. in Biology from Bucknell University and has attended executive education programs at Duke, Northwestern and Harvard.

Scientific Board

Sampath Parthasarathy, Ph.D., University of Central Florida

Dr. Parthasarthy is one of the “fathers” of the antioxidant theory from his work in the 1980s at the University of California-San Diego. He has published extensively in this field and has coauthored over 300 publications and book chapters in his career. He moved to Orlando, Florida in 2011 and presently serves as Associate Director of Research at the University of Central Florida College of Medicine. He is also a co-founder of InVasc Therapeutics, a drug development company that is focused on metabolic diseases.

Jaipal Singh, Ph.D., CEO, Prana Biotech

Dr. Singh has had a distinguished career in pharmaceutical development. He served as a senior scientist for Eli Lilly in Indianapolis, Indiana. He is the immediate past Chief Scientific Officer for the Saint Joseph Translational Research Institute in Atlanta. Dr. Singh has published nearly 100 papers and has received extensive financial support from the National Institutes of Health and the pharmaceutical industry. He is also Adjunct Professor of Biomedical Sciences at Georgia Institute of Technology in Atlanta.

Tarek Saleh, Ph.D. University of Prince Edward Island

Dr. Saleh continues to serve as a close collaborator with Dr. Khan and is a co-inventor for CAR-208. He is presently Chairman of Biomedical Sciences at UPEI. Dr. Saleh has published extensively in internationally renowned neuroscience journals and has considerable funding from the Canadian Institute of Health Research.

Martin Thoenes, M.D. Edwards Lifesciences-Europe

Dr. Thoenes has an extensive professional career in pharmaceutical development and in the cardiometabolic space. He served as Medical Director of Atherosclerosis and Diabetes Development at Sanofi-Aventis in Paris (2002-2006) and then in Shanghai, China (2006-2010). In addition, he serves as Associate Professor of Pharmacology at the Technikal University in Dresden, Germany. Dr. Thoenes is director of education for Edwards Lifesciences-Europe in Geneva, Switzerland and is focused on coating of drug products on devices such as stents. He has published several highly regarded scientific papers and is well regarded at international medical conferences.